(self.webpackChunk_N_E=self.webpackChunk_N_E||[]).push([[475],{1624:(e,t,r)=>{"use strict";r.d(t,{A:()=>i});let i=(0,r(9774).A)("circle-alert",[["circle",{cx:"12",cy:"12",r:"10",key:"1mglay"}],["line",{x1:"12",x2:"12",y1:"8",y2:"12",key:"1pkeuh"}],["line",{x1:"12",x2:"12.01",y1:"16",y2:"16",key:"4dfq90"}]])},3444:(e,t,r)=>{"use strict";r.d(t,{aC:()=>l,kv:()=>o,zv:()=>n});var i=r(9370);let n=["Proponent","Bentrio","Smertebehandling"],s=[{title:"Nordiske Pharma Trender Q2",url:"#",publisher:"PharmaNordic Insights",publishedAt:"2023-10-15"},{title:"Regulatorisk oppdatering: Nasal levering",url:"#",publisher:"EMA Monitor",publishedAt:"2023-10-12"},{title:"Konkurrentanalyse: Smertebehandling",url:"#",publisher:"GlobalData",publishedAt:"2023-10-10"},{title:"Kliniske studieretultater Fase III",url:"#",publisher:"ClinicalTrials.gov",publishedAt:"2023-09-28"},{title:"Markedstilgangsrapport Norge",url:"#",publisher:"Legemiddelverket",publishedAt:"2023-10-01"},{title:"Helsebudsjett 2024",url:"#",publisher:"Det Danske Sundhedsministerium",publishedAt:"2023-10-05"}],a=function(e,t,r,n,a,l,o){let d=arguments.length>7&&void 0!==arguments[7]?arguments[7]:0;return{id:e,title:t,type:r,track:n,relatedProducts:a,markets:l,scores:{impact:Math.floor(3*Math.random())+7,risk:r===i.X.RISK?Math.floor(4*Math.random())+6:Math.floor(3*Math.random())+1,credibility:Math.floor(2*Math.random())+8},significanceScore:o,whyBullets:["P\xe5virker direkte omsetningsprognosene for Q4 med estimert 15%.","Samsvarer med strategisk skifte mot ikke-invasive leveringsmetoder.","Mulighet for first-mover advantage hvis vi handler innen 30 dager."],recommendedNextSteps:["Planlegg briefing med Medisinsk avdeling ang\xe5ende nye data.","Oppdater presentasjoner for Key Account Managers f\xf8r Q1-syklusen.","Gjennomg\xe5 prisstrategien for det norske markedet."],sources:[s[Math.floor(Math.random()*s.length)],s[Math.floor(Math.random()*s.length)]],createdAt:(e=>{let t=new Date;return t.setDate(t.getDate()-e),t.toISOString()})(d),fitScore:n===i.C.PORTFOLIO?Math.floor(20*Math.random())+75:void 0}},l=[a("p1","Bentrio: Uventet mangelsituasjon hos konkurrent i Norge skaper \xe5pning",i.X.OPPORTUNITY,i.C.PRODUCT,["Bentrio"],["NO"],95,0),a("p2","Proponent: Nye refusjonsretningslinjer i Danmark favoriserer v\xe5r profil",i.X.OPPORTUNITY,i.C.PRODUCT,["Proponent"],["DK"],92,1),a("p3","Smertebehandling: Forsinkelse i konkurrents Fase III-resultater",i.X.OPPORTUNITY,i.C.PRODUCT,["Smertebehandling"],["SE","NO"],88,10),a("p5","Bentrio: Positive Real-World Evidence-data publisert",i.X.EVIDENCE,i.C.PRODUCT,["Bentrio"],["NO","DK"],85,5),a("p6","Proponent: Konkurrent lanserer aggressiv priskampanje",i.X.RISK,i.C.PRODUCT,["Proponent"],["SE"],89,4),a("p7","Smertebehandling: Key Opinion Leader st\xf8tter v\xe5r virkningsmekanisme",i.X.TREND,i.C.PRODUCT,["Smertebehandling"],["DK"],82,15),a("l1","Skifte i fastlegers forskrivningsm\xf8nster mot forebyggende behandling",i.X.TREND,i.C.LANDSCAPE,[],["NO","SE"],88,1),a("l2","Nytt EU-b\xe6rekraftsdirektiv p\xe5virker emballasjekrav",i.X.RISK,i.C.LANDSCAPE,[],["NO","DK","SE"],85,30),a("l3","Konkurrent X kj\xf8per opp lokal distribut\xf8r i Sverige",i.X.TREND,i.C.LANDSCAPE,[],["SE"],90,2),a("l4","Oppdaterte EAACI-retningslinjer anbefaler tidligere intervensjon",i.X.EVIDENCE,i.C.LANDSCAPE,[],["DK","NO"],93,5),a("l5","Bruk av telehelse flater ut i distriktene",i.X.TREND,i.C.LANDSCAPE,[],["NO"],75,40),a("l8","Konkurrent Y nedbemanner salgsstyrken i Norden",i.X.OPPORTUNITY,i.C.LANDSCAPE,[],["NO","DK","SE"],86,3),{...a("port1","BioTech Alpha: Ny plattform for nasal levering (Serie B)",i.X.PARTNER,i.C.PORTFOLIO,[],["SE"],94,2),status:"NEW"},{...a("port2","NeuroSol: Migrene-ressurs komplement\xe6r til Smertebehandling",i.X.PARTNER,i.C.PORTFOLIO,[],["DK"],91,10),status:"REVIEW"},{...a("port3","AllergyAI: Digitalt diagnostikkverkt\xf8y for pasientstratifisering",i.X.PARTNER,i.C.PORTFOLIO,[],["NO"],88,0),status:"NEW"},{...a("port4","GenericCo: Potensielt salg av eldre respiratorisk portef\xf8lje",i.X.PARTNER,i.C.PORTFOLIO,[],["SE"],83,40),status:"DUE_DILIGENCE"}];i.C.PRODUCT,l.filter(e=>e.relatedProducts.includes("Proponent")),i.C.PRODUCT,l.filter(e=>e.relatedProducts.includes("Bentrio")),i.C.PRODUCT,l.filter(e=>e.relatedProducts.includes("Smertebehandling")),i.C.LANDSCAPE,l.filter(e=>e.track===i.C.LANDSCAPE),i.C.PORTFOLIO,l.filter(e=>e.track===i.C.PORTFOLIO&&"NEW"===e.status);let o=[{productId:"Proponent",period:"2023-10",revenue:12.5,targetRevenue:12,marketShare:24.8,mediaMentions:[{id:"m1",title:"Refusjonsendringer skaper debatt blant fastleger",source:"Dagens Medisin",date:"2023-10-14",url:"#",sentiment:"positive",snippet:"...de nye reglene gj\xf8r at Proponent seiler opp som et mer kostnadseffektivt alternativ for pasienter med kroniske..."},{id:"m2",title:"Priskrig p\xe5 allergimedisiner i Sverige",source:"L\xe4kemedelsv\xe4rlden",date:"2023-10-10",url:"#",sentiment:"negative",snippet:"...flere akt\xf8rer presser prisene, noe som kan g\xe5 utover marginene til etablerte merkevarer i segmentet..."},{id:"m3",title:"Pasientforeningen hyller ny bivirkningsprofil",source:"NRK Livsstil",date:"2023-10-05",url:"#",sentiment:"positive",snippet:"...endelig et alternativ som ikke gir d\xf8sighet, sier lederen i foreningen..."},{id:"m4",title:"Q3-tallene for farmasi-sektoren",source:"Finansavisen",date:"2023-10-01",url:"#",sentiment:"neutral",snippet:"...sektoren viser stabil vekst tross makro\xf8konomisk uro..."}]},{productId:"Bentrio",period:"2023-10",revenue:8.2,targetRevenue:7.5,marketShare:15.3,mediaMentions:[{id:"b1",title:"Tomme hyller for konkurrent - Bentrio tar over",source:"Apotek1.no",date:"2023-10-12",url:"#",sentiment:"positive",snippet:"...grunnet leveringsproblemer anbefales n\xe5 Bentrio som prim\xe6r substitutt i alle v\xe5re filialer..."},{id:"b2",title:"Studie bekrefter effekt av nasal barriere",source:"Forskning.no",date:"2023-10-08",url:"#",sentiment:"positive",snippet:"...ny forskning viser at mekanisk barriere er like effektivt som milde antihistaminer..."}]},{productId:"Smertebehandling",period:"2023-10",revenue:0,targetRevenue:0,marketShare:0,mediaMentions:[]}]},5104:(e,t,r)=>{Promise.resolve().then(r.bind(r,7646))},7646:(e,t,r)=>{"use strict";r.r(t),r.d(t,{default:()=>k});var i=r(9700),n=r(1464),s=r(9370),a=r(3444),l=r(8598),o=r(5744),d=r(4270),m=r(1470),p=r(5479),u=r(1624),c=r(246);let g=e=>{let{onItemClick:t,initialProduct:r,financials:g}=e,[k,f]=(0,n.useState)(a.zv[0]);(0,n.useEffect)(()=>{r&&a.zv.includes(r)&&f(r)},[r]);let{data:h,isLoading:v,error:b}=(0,l.rY)({track:s.C.PRODUCT,relatedEntity:k}),N=(0,n.useMemo)(()=>null==h?void 0:h.find(e=>e.track===s.C.PRODUCT&&e.relatedEntity===k),[h,k]),P=(0,n.useMemo)(()=>(null==h?void 0:h.filter(e=>e.relatedEntity===k))||[],[h,k]),x=(0,n.useMemo)(()=>g.find(e=>e.productId===k),[k,g]);return(0,i.jsxs)("div",{className:"flex flex-col h-full animate-in fade-in space-y-6",children:[(0,i.jsx)("div",{className:"sticky top-0 z-20 pt-2 pb-4 bg-[#f8fafc]/95 backdrop-blur-sm supports-[backdrop-filter]:bg-[#f8fafc]/60",children:(0,i.jsx)("div",{className:"flex justify-center",children:(0,i.jsx)("div",{className:"flex items-center p-1 bg-slate-200/60 rounded-xl shadow-inner border border-slate-200/50",children:a.zv.map(e=>{let t=k===e,r=(0,d.w)(e),n=r.icon;return(0,i.jsxs)("button",{onClick:()=>f(e),className:(0,m.cn)("flex items-center gap-2 px-6 py-2.5 rounded-lg text-sm font-bold transition-all duration-300",t?"bg-white text-slate-900 shadow-[0_2px_8px_-2px_rgba(0,0,0,0.1)] ring-1 ring-black/5 scale-[1.02]":"text-slate-500 hover:text-slate-700 hover:bg-slate-200/50"),children:[(0,i.jsx)(n,{size:16,className:(0,m.cn)("transition-colors",t?r.color:"text-slate-400"),strokeWidth:t?2.5:2}),e]},e)})})})}),(0,i.jsx)("div",{className:"flex-1 min-h-0 -mt-2",children:v?(0,i.jsxs)("div",{className:"flex flex-col items-center justify-center h-[500px] text-slate-400 bg-slate-50/50 rounded-2xl border border-dashed border-slate-200",children:[(0,i.jsx)(p.A,{size:48,className:"mb-4 opacity-20 animate-spin"}),(0,i.jsxs)("p",{className:"font-medium",children:["Laster rapport for ",k,"..."]})]}):b?(0,i.jsxs)("div",{className:"flex flex-col items-center justify-center h-[500px] text-red-400 bg-red-50/50 rounded-2xl border border-dashed border-red-200",children:[(0,i.jsx)(u.A,{size:48,className:"mb-4 opacity-20"}),(0,i.jsx)("p",{className:"font-medium mb-2",children:"Kunne ikke laste rapport"}),(0,i.jsx)("p",{className:"text-sm text-slate-500",children:b.message})]}):N?(0,i.jsx)(o.E,{report:N,financials:x,onItemClick:t,allReports:P}):(0,i.jsxs)("div",{className:"flex flex-col items-center justify-center h-[500px] text-slate-400 bg-slate-50/50 rounded-2xl border border-dashed border-slate-200",children:[(0,i.jsx)(c.A,{size:48,className:"mb-4 opacity-20"}),(0,i.jsxs)("p",{className:"font-medium",children:["Ingen rapport tilgjengelig for ",k,"."]})]})})]})};function k(){return(0,i.jsx)(g,{onItemClick:()=>{},financials:[]})}}},e=>{e.O(0,[732,558,252,479,744,789,290,358],()=>e(e.s=5104)),_N_E=e.O()}]);